acute pancreatitis
Conditions
Interventions
Celecoxib group:Routine treatment + oral or tube feeding of celecoxib 200mg twice daily for 7 days
Placebo group:Oral or tube feeding of placebo 200mg twice daily for 7 days
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis of AP1 requiring two of the following three features: (1) Abdominal pain consistent with AP (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) Serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; (3) Characteristic findings of AP on CT and less commonly MRI or abdominal ultrasonography; 2. Inpatients aged 18~80 years; 3. Onset of symptoms to enrollment no more than 48 hours; 4. Meet either of the following criteria: (1) SIRS (Systemic Inflammatory Response Syndrome) meeting any two or more of the following: 1) Heart rate > 90 beats/min; 2) Respiratory rate > 20 breaths/min or PaCO2 38°C or 12 × 10^9/L or 43% for males or > 39.6% for females; 3) Serum creatinine level above the upper limit of normal; 4) BMI >= 26 kg/m^2; 5) HbA1c >= 6.5%; 6) Age >= 60 years; 5. Modified Marshall score <2 for either organ.
Exclusion criteria
Exclusion criteria: 1. Known allergy to sulfonamide drugs, history of sulfonamide allergy; 2. Pregnancy and lactation; 3. The use of non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids within 2 weeks prior to enrolment; 4. Presence of severe underlying diseases or dysfunction in vital organs such as the heart, lungs, brain, or kidneys; 5. Severe digestive system diseases, including but not limited to: liver cirrhosis, esophageal varices, peptic ulcer with a history of gastrointestinal bleeding within the past month, ulcerative colitis, Crohn's disease, or chronic pancreatitis; 6. Participants who have been receiving cytotoxic drugs, immunosuppressants, radiotherapy, and chemotherapy for a long time; drug abuse or psychosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of organ failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of organ failure;Modified CT severity index;Safety assessment;Change in SOFA score;Organ Support Usage;Systemic inflammatory indicators;Clinical outcome measures;Incidence of MSAP and SAP; | — |
Countries
China
Contacts
Public ContactChengwei Tang
West China Hospital, Sichuan University
Outcome results
None listed